Notice of FY21 Trading Update

RNS Number : 0875A

Oncimmune Holdings PLC

28 May 2021

 

28 May 2021

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Notice of FY21 Trading Update

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, announces that it will issue a trading update for the year ended 31 May 2021 on 8 June 2021.

Analyst and investor presentations

Dr Adam M Hill, Chief Executive Officer and Matthew Hall, Chief Financial Officer will host an online presentation for analysts at 11:30am BST on 8 June 2021. For registration details please contact Alexander Davis of FTI Consulting at [e-mail] or 020 3727 1000.

Dr Adam M Hill and Matthew Hall will also host a live presentation on Investor Meet Company at 4:30pm BST on 8 June 2021 which will be open to all existing Oncimmune shareholders and potential new investors. Access to Investor Meet Company is free and interested parties are invited to register their attendance on the following link: https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor

Investors who already follow Oncimmune Holdings plc on the Investor Meet Company platform will automatically be invited. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am BST the day before the meeting or at any time during the live presentation.

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser)

Andrew Jones, Daniel Harris, James Hornigold

[phone]

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin

[phone]

WG Partners (Joint Broker)

David Wilson, Claes Sp å ng

[phone]

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners .

Our understanding of the immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.

Oncimmune's ImmunoINSIGHTS platform enables life science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, and has a discovery research centre in Dortmund, Germany.

For more information, visit  www.oncimmune.com

 

END

 

 

NOREALSXAFFFEFA